DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY. et al.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced nonsmall-cell lung cancer (KEYNOTE-010): A randomised controlled trial.
Lancet 2016;
387: 1540-50
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.